Halozyme Therapeutics

$49.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.00 (+4.21%) Today

$0.00 (0.00%) As of 11:35 AM UTC after-hours

Why Robinhood?

You can buy or sell HALO and other stocks, options, and ETFs commission-free!

About HALO

Halozyme Therapeutics, Inc. Common Stock, also called Halozyme Therapeutics, is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA. The listed name for HALO is Halozyme Therapeutics, Inc. Common Stock.

CEO

Helen I. Torley

Employees

132

Headquarters

San Diego, California

Founded

1998

Market Cap

6.72B

Price-Earnings Ratio

322.69

Dividend Yield

—

Average Volume

1.51M

High Today

$49.55

Low Today

$46.75

Open Price

$46.78

Volume

947.12K

52 Week High

$49.55

52 Week Low

$12.71

Collections

Analyst Ratings

83%

of 12 ratings

Buy

83%

Hold

Sell

HALO Earnings

-$0.24

-$0.08

$0.09

$0.25

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Available Feb 23, After Hours